NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402

Authors: Laura Donovan, Minhee Won, J Gregory Cairncross, Fabio Iwamoto, Jan Buckner, Karen Fink, Jean-Paul Bahary, Alan Hartford, Luis Souhami, Timothy Nguyen, Terrence Cescon, Mark Mishra, Igor Barani, Anthony Pu, Wilson Roa, Jiayi Huang, Mei Polley, Minesh Mehta

Published: 2021-11-18

DOI: 10.1093/neuonc/noab196.603

Source: Full article

NCOG-12. COGNITIVE FUNCTION (CF) &amp; QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, &amp; VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402

Abstract

NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402